Life expectancy of most patients with differentiated thyroid cancer is normal, so adverse treatment effects should be minimized. Lower activities of radioiodine for ablation of thyroid remnants are non-inferior to higher activities and quality of life can be maintained by preparation of radioiodine remnant ablation using recombinant human thyrotropin.
Key Points
In accordance with previous studies on the use of recombinant human thyrotropin and recent studies comparing low and high activities of 131I for ablation of thyroid remnants in patients with differentiated thyroid cancer (DTC) with and without the use of recombinant human thyrotropin, guidelines recommending high activities of 131I for ablation in hypothyroidism for patients with low-risk DTC probably need to be rewritten.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
National Cancer Institute. Surveillance, Epidemiology and End Results [online], (2011).
Verburg, F. A. et al. No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 37, 276–283 (2012).
Reiners, C., Hänscheid, H., Luster, M., Lassmann, M. & Verburg, F. A. Radioiodine for remnant ablation and therapy of metastatic disease. Nat. Rev. Endocrinol. 7, 589–595 (2011).
Mallick, U. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012).
Schlumberger, M. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366, 1663–1673 (2012).
Alexander, E. K. & Larsen, P. R. Radioiodine for thyroid cancer—is less more? N. Engl. J. Med. 366, 1732–1733 (2012).
Sawka, A. M. et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19, 451–457 (2009).
Pacini, F. et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J. Clin. Endocrinol. Metab. 91, 926–932 (2006).
Schroeder, P. R. et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab. 91, 878–884 (2006).
Hänscheid, H. et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med. 47, 648–654 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C. Reiners and M. Luster have received lecture fees from Genzyme.
Rights and permissions
About this article
Cite this article
Reiners, C., Luster, M. Radioiodine in thyroid cancer—how to minimize side effects. Nat Rev Clin Oncol 9, 432–434 (2012). https://doi.org/10.1038/nrclinonc.2012.101
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.101
